In the original article, in Section 3.1.1, the term “carbapenemases” was associated with Class C β-lactamases instead of Class B β-lactamases in two sentences (Page 10762). In Table 2 (Pages 10764–10765), AmpC was given as an example of Class D noncarbapenemases instead of Class C noncarbapenemases. These small mistakes due to oversight have been rectified below. The authors apologize for the error.
Table 2. β-Lactamase Inhibitors (Approved and in Clinical Development).
Rectified Statements and Modified Table 2
Even though clavulanic acid shows activity against Class A and D β-lactamases, it lacks any activity against Class A, B, D carbapenemases and Class C β-lactamases.55 Thereafter, two more β-lactamase inhibitors based on the β-lactam core, sulbactam (2) and tazobactam (3) were discovered in the 1980s.56 However, they also do not cover carbapenemases within their spectrum. In 2015, avibactam (4), a diazabicyclooctane (DBO) was approved by the FDA as a potent inhibitor of many serine β-lactamases (Type A, C and D), however, lacking activity against certain Class B and D carbapenemases.57